Kornimate/medical-research-clean huggingface dataset:
rad predictors for won

Conditions: Walled Off Pancreatic Necrosis (WON)

Summary: this is a retrospective chart review study examining 1) demographic data such as age, sex, etiology of pancreatitis 2) clinical data including radiological characteristics of walled off pancreatic necrosis, walled off necrosis related admissions and readmission following endoscopic drainage, surgical or percutaneous procedures performed for the management of walled off pancreatic necrosis, and clinical outcomes following treatment of won (including hospital readmissions, won resolution, procedure complications, won related death) 3) endoscopy data including indication for initial endoscopic drainage and subsequent endoscopic procedures performed for management of walled off necrosis (including additional egd's, endoscopic drainage procedures, and/or necrosectomy)


Eligibility criteria:
inclusion criteria: * patients over 18 years of age who underwent endoscopic drainage of walled off pancreatic necrosis * patients who did not require further intervention (either surgical, percutaneous, or endoscopic) following endoscopic drainage * patients who required further intervention for walled off pancreatic necrosis (either surgical, percutaneous, or endoscopic) following endoscopic drainage. * patients who underwent percutaneous or surgical interventions prior to endoscopic drainage exclusion criteria: * pancreatic pseudocysts without any solid debris * under 18 years of age at the time of endoscopic drainage
image and dosimetry related research of department of medical physics, cross cancer institute

Conditions: Healthy

Summary: the purpose of this study is to retrospectively have access to image files of patients.


Eligibility criteria:
inclusion criteria: * subject 18 years of age and over
treatment of social phobia

Conditions: Phobic Disorders; Social Phobia; Public Speaking Anxiety

Summary: social phobia is a very common and debilitating disorder, with public speaking anxiety being the most common fear. psychologists have found that treating patients for their fear of public speaking, through cognitive-behavioral treatment (talk-based therapy) or exposure treatment (where participants participate in actual public speaking sessions), not only helps patients overcome this fear but also helps them overcome their more general social fears. however, little is known about how this change occurs during therapy. this study tries to identify the factors that contribute most to successful therapy. patients are assigned randomly (like tossing a coin) to 1 of 3 groups. group 1 will receive cognitive-behavioral treatment and group 2 will receive exposure treatment. group 3 will not receive treatment. study leaders will monitor patient response to treatment through behavioral tests and assessments. an individual may be eligible for this study if he/she: has social phobia with public speaking anxiety.

the primary goal of the present study is to identify the mediators and moderators of change in the treatment of social phobia and, in so doing suggest a common mechanism of action for all brief psychosocial interventions. perceived self-efficacy of social behavior, negative cognitive appraisal (estimated social costs), and perceived emotional control will be considered as potential mediators; avoidant personality disorder and the generalized subtype of social phobia will be considered as potential predictors for poor treatment outcome. social phobia is a very prevalent and debilitating disorder, with public speaking anxiety being the most common fear among socially phobic individuals. although there are a number of effective psychosocial treatments for social phobia (e.g., cognitive-behavioral treatments and exposure therapy) very little is known about the underlying mechanism of therapeutic change (i.e., the mediators of change), and the variables that are predictive of treatment outcome (i.e., the moderators of change). furthermore, it is unclear why treating individuals for their public speaking anxiety can generalize to other untreated social fears. patients are randomly assigned to either a comprehensive cognitive-behavioral treatment for social phobia (n=43), a performance-based exposure treatment for public speaking anxiety without cognitive intervention (n=43), or a waitlist control group (n=43). clinician ratings, behavioral tests, cognitive assessments, subjective ratings, and physiological measures are employed to determine the degree of therapeutic gains in various social phobia domains. the main hypothesis is that perceived emotional control will mediate treatment outcome and generality of effectiveness independent of the specific treatment condition.

Eligibility criteria:
inclusion criteria: - patients must have: social phobia with public speaking anxiety.

Keywords: cognitive therapy cost of illness female human male phobic disorders phobic disorders -- *therapy phobic disorders -- pathology
safety study of oral sodium phenylbutyrate in subjects with als (amyotrophic lateral sclerosis)

Conditions: Amyotrophic Lateral Sclerosis

Summary: the purpose of the study is to evaluate the safety of sodium phenylbutyrate (napb) treatment in subjects with amyotrophic lateral sclerosis (als) and the ability to take this medication without major side effects.

although it is known that nerve cells die in the brains and spinal cords of patients who have als, the cause of the cell death is unknown. there is evidence that this cell death may be caused by changes in dna, the body's genetic material. drugs such as sodium phenylbutyrate (napb) can increase the expression of genes, block how the motor nerve cells in als die, and may prove to be an effective therapy for als. napb has shown an improvement in survival in mice with conditions similar to als. study design: all research participants will take sodium phenylbutyrate for a total of 20 weeks. the dose of medication will be increased every 2 to 4 weeks until a maximum, easily tolerated dose is achieved (study maximum is 21 g/day).

Eligibility criteria:
inclusion criteria: * diagnosed with als * at least 18 years of age * women, who can become pregnant, must actively use effective birth control measures exclusion criteria: * must not have any other neurological (nervous system) disease veterans only are eligible to participate at va sites.

Keywords: als histone deacetylase inhibition open label safety study sodium phenylbutyrate
the impact of theory-based messaging on covid-19 vaccination intentions

Conditions: Vaccination; Covid19

Summary: uptake of vaccination against covid-19 is key to controlling the pandemic. however, a significant proportion of people report that they do not intend to have a vaccine, often because of concerns they have about its side effects or safety. it is important to identify ways to communicate information about the vaccines that facilitate informed decisions rather than promoting uptake through coercion. this study will assess whether theory-based messages can change beliefs and increase intentions to receive a covid-19 vaccine in scotland. the messages will be based on publicly available information about the need for covid-19 vaccination and the safety of the vaccines, and structured to address specific types of treatment beliefs. participants will be randomised to either a group shown the messages or a control group shown general information messages about the covid-19 virus and vaccination programme. by comparing the two groups we aim to test what impact the theory-based messages have on intentions and beliefs about covid-19 vaccination.


Eligibility criteria:
inclusion criteria: * willing and able to give informed consent for participation in the trial * aged 18 years or above * resident in scotland exclusion criteria: * received at least one covid-19 vaccination dose

Keywords: vaccine hesitancy vaccination uptake messaging illness beliefs treatment beliefs
adaptive physical activity for chronic stroke

Conditions: Stroke

Summary: this study will compare the adaptive physical activity program (apa) to a less vigorous group exercise program, (sittercise) to see if apa leads to greater improvements in walking endurance, quality of life, and participation in social activities.

the purpose of this study is to translate the italian apa exercise model into a sustainable, evidence-based va community program of exercise for older adults with chronic stroke. the investigators' short-term objectives are to test study hypotheses using a randomized clinical trial (rct) with an attention control (also referred to as the "sittercise" exercise program). the investigators will also explore factors related to exercise adherence in a community program for chronic stroke survivors. the investigators' longer term objective is to disseminate this model to facilitate the development of a network of community-based exercise programs for older adults with chronic stroke. in the rct the investigators propose to offer courses in office of aging (ooa) senior centers and national rehabilitation hospital. at the conclusion of the research study, the ooa plans to continue offering apa-stroke courses. through partnership, the veterans health administration (vha) and the administration of aging (aoa) can potentially replicate this model at the community throughout the u.s. using local ooa senior centers and other facilities that would increase community access for veterans.

Eligibility criteria:
inclusion criteria: * evidence of stroke (ischemic or hemorrhagic) minimum 6 months prior in men or women ages 40 or older; * residual hemiparetic gait deficits; * already completed all conventional inpatient and outpatient physical therapy; * ability to rise from a chair unaided and without an assistive device exclusion criteria: * cardiac history of active unstable angina, recent (less than 3 months) myocardial infarction, or congestive heart failure (nyha category ii or higher); * orthopedic, circulatory, or chronic pain conditions restricting exercise; * active cancer; poorly controlled hypertension ( greater than 180/100 on 2 readings separated by 5 minutes rest); * dementia; * severe receptive or global aphasia with inability to follow 2-step commands; * co-morbid non-stroke neurological disorder that impairs mobility (e.g. multiple sclerosis or parkinson's); * untreated clinical depression; * inability to complete the "6-minute walk" test during baseline testing

Keywords: stroke exercise
renoprotective effect of nisoldipine and lisinopril in type 1 diabetic nephropathy

Conditions: Diabetic Nephropathy

Summary: the aim of the study was to compare the renoprotective effect of a long acting calcium antagonist (nisoldipine) with an angiotensin converting enzyme inhibitor (lisinopril)in type 1 diabetic patients with diabetic kidney disease. in total, 51 patients were randomised to treatment with one of these drugs for 4 years. changes in kidney function, blood pressure and urinary excretion of albumin were measured every 6 months


Eligibility criteria:
inclusion criteria: * diabetic nephropathy, type 1 diabetes, hypertension exclusion criteria: * child bearing potential, non-diabetic kidney disease, malignancy
cholecyst- versus cystic duct cholangiography during laparoscopic cholecystectomy

Conditions: Laparoscopic Cholecystectomy; Gall Stone Disease; Biliary Tract Anatomy; Common Bile Duct Stones.

Summary: standard cystic duct cholangiography (cdc) during laparoscopic cholecystectomy can be difficult, time consuming and bile duct injury may be caused by attempts to cannulate the cystic duct. operative cholangiography performed by direct puncture of the gall bladder fundus or cholecystocholangiography (ccc) is a valid and easier alternative.

this study was conducted on 60 patients with symptomatic gall bladder stones undergoing laparoscopic cholecystectomy. patients were randomized into two groups: group (1) was evaluated by cholecyst-cholangiography by puncture through the gall bladder fundus. group (2) was evaluated for the standard cystic duct cholangiography.cholangiography was considered successful if it could be performed with complete delineation of the biliary tree with flow of the dye through the duodenum occurred. it is to be noted that inability to cannulate the cystic duct for example, is considered a failure.

Eligibility criteria:
inclusion criteria: * patients with symptomatic gall bladder stones. exclusion criteria: * unfit patients and/or had previous surgery * history of obstructive jaundice and acute attacks or previous ercp were excluded

Keywords: laparoscopic cholecystectomy intra-operative cholangiography
electromagnetic field therapy to improve healing of chronically venous ulcer

Conditions: Chronic Venous Hypertension With Ulcer and Inflammation; Venous Ulcer Pain

Summary: chronically venous ulcer in lower extremities is a permanent and disabling disease. venous insufficience is the main cause of chronic ulcer. there is a high prevalence and frequency of the disease, primarily among elderly people. recently, electromagnetic field therapy has been tested on various diseases in musculoskeletal system with a beneficial effect. in recent years, there has been an increasing interest in using electromagnetic field therapy to treat chronically venous ulcer. the hypothesis of the investigators is that the electronic magnetic field therapy improves the healing process and reduces pain for patients suffering from chronically venous ulcer. the investigators assume that the bioactivity is affected by a cellular response which affects the dna synthesis, transcription og protein synthesis.


Eligibility criteria:
inclusion criteria: * patients who suffer from ulcer in lower extremities * patients who suffer from venous insufficience detected by duplex scanning or by a pressure on digits \> 40 mmhg * patients with a regular need of compression stockings * age \> 18 years exclusion criteria: * age \< 18 years * unability to read or understand danish * patients who suffer from manifest neoplastic disorder

Keywords: electromagnetic field therapy chronically venous ulcer venous insufficiens
td-1473 absorption, distribution, metabolism and excretion (adme) study in healthy male subjects

Conditions: Intestinal Disorders; Bowel Diseases, Inflammatory

Summary: this is an open-label, 2-cohort study to evaluate the absolute bioavailability, absorption, distribution, metabolism and excretion of td-1473 in healthy male subjects. subjects in cohort 1 will receive a single oral dose of td-1473 and a single intravenous bolus dose of \[14c\]-td-1473. subjects in cohort 2 will receive a single oral dose of \[14c\]-td-1473 only.


Eligibility criteria:
inclusion criteria: * subject is a healthy, nonsmoking male, 19 to 55 years old, inclusive * subject has a body mass index (bmi) 19 to 32 kg/m2, inclusive, and weighs at least 50 kg * subject is healthy as determined by the pi or designee based on medical history and physical examination performed at screening and day -1 * additional inclusion criteria apply exclusion criteria: * subject has any condition possibly affecting drug absorption (e.g., previous surgery on the gastrointestinal tract \[including removal of parts of the stomach, bowel, liver, gall bladder, or pancreas\]) * subject has a known hypersensitivity towards medications similar to td 1473 or excipients contained in td 1473 * subject regularly works with ionizing radiation or radioactive material * subject has been exposed to ionizing radiations, within 1 year prior to the start of the study, as external irradiation (i.e., radiological examination including ct scan, excluding dental radiography) or internal radiation (i.e., diagnostic nuclear medicine procedure) or have participated in a radiolabeled study in the last 12 months * subject, who, for any reason, is deemed by the pi or designee or sponsor to be inappropriate for this study or have any condition which would confound or interfere with the evaluation of the safety, tolerability, and pk of the investigational drug or prevent compliance with the study protocol * additional exclusion criteria apply

Keywords: absolute bioavailability adme healthy normal males
effect of an interdisciplinary spine rehabilitation program

Conditions: Low Back Pain; Spine Disease

Summary: the goal of this research project is to evaluate the effectiveness of the current interdisciplinary rehabilitation program (revita) and follow-up trajectory for chronic lumbar spine disorders in the university hospitals leuven.


Eligibility criteria:
inclusion criteria * adults, age \> 18 years * spine problem for \> 6 weeks, needing interdisciplinary care (risk factors, failure of first line treatment, etc) * inclusion in revita program * informed consent to participate exclusion criteria * patients without sufficient understanding of the dutch language * unable to participate in 2h rehabilitation sessions with exercises
the lumbar trident study

Conditions: Facet Joint Pain

Summary: this observational retrospective study evaluates the efficacy of rf with the three-tined expandable electrode needle compared to before treatment in the treatment of chronic lumbar facet joint pain.


Eligibility criteria:
inclusion criteria: * age \> 18 years old * patients with lumbar pain * patient who had two diagnostic medial branch blocks with significant (\>50%) improvement on both injections exclusion criteria: - no patient related outcome measures available in hospital's patient charts
probiotic supplement versus placebo for the treatment of patients with non-alcoholic fatty liver disease

Conditions: Fatty Liver, Nonalcoholic

Summary: probiotic supplement versus placebo for the treatment of patients with non-alcoholic fatty liver disease: a randomized, double-blind, placebo-controlled trial

probiotic supplement versus placebo for the treatment of patients with non-alcoholic fatty liver disease: a randomized, double-blind, placebo-controlled trial by access liver biochemistry, mri-pdff, fibroscan and metabolic profile

Eligibility criteria:
inclusion criteria: male and female adults ≥20,\<80 years of age who suspected or confirmed diagnosis of nash/nafld suggested by the historical data, they must meet one of the following criteria: fatty liver by imaging then fibroscan with cap ≥ 248 db m liver biopsy compatible with nash/nafld exclusion criteria: 1. supplement with probiotic/prebiotic within 2 weeks 2. previous antibiotic/antifungus within 1 month 3. history of significant alcohol consumption for a period of more than three consecutive months within 1 year before screening. significant alcohol consumption is defined as equal to or greater than approximately two alcoholic drinks per day for males and approximately 1.5 alcoholic drinks per day for females 4. regular use of drugs historically associated with nafld, which include, but are not limited, to the following: amiodarone, methotrexate, systemic glucocorticoids at greater than 5 mg/d 5. chronic liver diseases from other cause such as viral hepatitis, autoimmune hepatitis 6. hepatic decompensation or impairment defined as presence of any of the following: * history of esophageal varices, ascites or hepatic encephalopathy. * serum albumin \<3.5 g dl-1, except as explained by nonhepatic causes. * inr \> 1.4 7. use of glp-1 agonist therapy (for example, exenatide, liraglutide, lixisenatide, albiglutide, dulaglutide, semaglutide and albiglutide), vitamin e and pioglitazone 8. active autoimmune disease, including actively treated lupus, rheumatoid arthritis, inflammatory bowel disease 9. active malignancy on treatment 10. new york heart association class iii or iv heart failure or known left ventricular ejection fraction \<30% 11. known immunocompromised status, hiv or who have recurrent or chronic systemic bacterial, fungal, viral or protozoal infections 12. respiratory compromised 13. severe renal impairment (egfr \<30 ml/min/1.73 m2) 14. pregnancy

Keywords: probiotic
validity of pain threshold index in children

Conditions: Electroencephalography; Anesthesia, General

Summary: comparison of total infused dose of remifentanil between pain threshold index monitoring group and control group

investigators plan to enroll pediatric patients aged between 3 and 12 years old undergoing surgery under general anesthesia with continuous infusion of 2% propofol and remifentanil. after dividing them into two groups, investigators monitor pain threshold index and wavelet index in test group and adjust remifentanil infusion to maintain both indices in desirable range, while monitoring only wavelet index and adjust remifentanil infusion to maintain wavelet index and conventional vital signs in desirable range in control group. investigators compare consumption of remifentanil, time to extubation after surgery, and post-anesthesia care unit length of stay between both groups.

Eligibility criteria:
inclusion criteria: * children between 3 and 12 years old undergoing orthopedic surgery at extremities under general anesthesia exclusion criteria: * history of adverse drug reactions to opioids * underlying neurological disease or taking medication for neurologic purpose * patients who were transferred to intensive care unit after the surgery
early diagnosis of therapy-associated cardiotoxicity basing on multi-tracer multimodality pet/mri

Conditions: Positron-Emission Tomography; Magnetic Resonance Imaging

Summary: using multi-tracer to early diagnosis of therapy-associated cardiotoxicity using multimodality pet/mri.

in this study investigators evaluated cardiac uptake by different molecular probe such as fdg, fapi-04 using multimodality pet/mri. previous studies have shown that increased cardiac uptake of fdg on pet may be an indicator of myocardial injury after chemotherapy. cardiac magnetic resonance (cmr) allows for multiparametric evaluation of cardiac morphology, ventricular function, myocardial perfusion, and viability. the combination of pet with mr (pet/mr) is therefore an alternative attractive pairing for diagnostic imaging. the aim of this study is to find noninvasive and effective method for early diagnosis of cardiotoxicity after chemotherapy or immunotherapy

Eligibility criteria:
inclusion criteria: * availability of a clinical pre- and post-therapy clinical evaluation encompassing electrocardiogram (ecg) ; * normal findings at pre-therapy clinical evaluation; * cancer planned chemotherapy or immunotherapy scheme ; * available staging fdg-pet/ct scan (pet0); exclusion criteria: * cannot lie supine for half an hour; * refuse to join the clinical researcher; * without metal implants.

Keywords: positron-emission tomography cardiotoxicity magnetic resonance imaging fdg fapi